SCHLAGWORTE: Life Sciences
GeneNovate Investors‘ Day 2026
Der GeneNovate Investors' Day findet parallel zum bio:cap Life Science & AI Investival vom 9. bis 11. Juni 2026 im CityCube Berlin statt. Weitere...
Impact Life Sciences Deep Dive 2026
Am 22. Juni 2026 veranstalten wir gemeinsam mit EY in München (invite only) den ersten Impact Life Sciences Deep Dive 2026. Freuen Sie sich...
Der Startschuss für eine neue Gründerära
Deutschland steht vor einer strukturellen Herausforderung: Während das Land in der akademischen Grundlagenforschung weltweit eine führende Rolle einnimmt, besteht bei der Übersetzung dieser Erkenntnisse...
Germany is emerging as a hub for nuclear medicine
Theranostics is on the rise and is becoming an exciting investment opportunity for private equity firms and other investors. In Germany, the Dresden’s Radiopharmaceutical...
Europa hat die Forschung. Aber warum fließt die große Wertschöpfung oft...
Europa verfügt über exzellente Forschung, führende Universitäten, renommierte Kliniken und eine dynamische Start-up-Landschaft in den Life Sciences. Gleichzeitig verändert Künstliche Intelligenz die Biotech- und...
Microcirculation is key
The mission of the Swiss biopharmaceutical Topadur is not only to dilate blood vessels, but also to cause them to regenerate. Its innovative drugs,...
The ultimate funding hack? A real value proposition and strong industry...
Public funding mitigates risks, but it cannot replace equity. Life sciences founders who merely jump from one funding deadline to the next, or who...
Capital for scientists: navigating the German funding maze strategically
Drug development, medical technology, or digital health: few industries are as capital-intensive as the life sciences. Yet, knowing precisely when to submit which application...
Swiss Biotech Day 2026 in Basel
The Swiss Biotech Day 2026 has kicked off in Basel from May 4-5, once again positioning Switzerland at the center of the global biotech...
Swiss biotech report: Robust performance in 2025
Switzerland’s biotech sector delivered a robust performance in 2025, underlining its resilience in a challenging global environment. According to the Swiss Biotech Report 2026,...
mbiomics erhält weitere 12 Mio. EUR
Das Start-up mbiomics, das skalierbare, mikrobiombasierte Therapeutika für schwere und chronische Erkrankungen entwickelt, hat im dritten Abschluss seiner Serie-A-Finanzierungsrunde weitere 12 Mio. EUR eingesammelt. ...
Brussels‘ biotech offensive: an overdue signal with flaws
Together with leading chinical research and legal experts, we analyse: is Brussels' 75-day fast-track enough to stop the innovation drain, or does the lack...
Onyx Biotech erhält Kapital für High-Tech Medikamentenentwicklung
Onyx Biotech erhält Pre-Seed-Kapital von Life Science Valley Wachstumsfonds, Freiraum Ventures und Business Angels für seine moderne Medikamentenentwicklung.
Onyx Biotech entwickelt best-in-class Algorithmen und Workflows,...
Financing research – even retrospectively
When the pandemic broke out in 2020, medical research around the world was under intense pressure. Everything had to happen at once: the so-called...
‚Life sciences are the ultimate impact investment‘
Robin Lauber is a third-generation heir, serial entrepreneur, and investor. Since 2015, he has developed the single-family office Infinitas Capital into a vertically integrated...